Deep in ‘the Cave,’ Lilly’s CEO Decided Alzheimer’s Drug’s Fate
This article is for subscribers only.
They called it “the cave.”
In an unmarked room in the middle of Eli Lilly & Co.’s Indianapolis campus, researchers holed up for months in 2012 poring over data from the company’s failed trials of its experimental Alzheimer’s disease treatment, solanezumab, looking for hidden signs the drug had worked.